Marshall Fordyce Sells 14,471 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 14,471 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total value of $575,366.96. Following the completion of the sale, the chief executive officer now owns 322,667 shares of the company’s stock, valued at approximately $12,829,239.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Vera Therapeutics Trading Up 0.5 %

Shares of NASDAQ VERA traded up $0.18 during midday trading on Friday, hitting $39.30. The stock had a trading volume of 301,331 shares, compared to its average volume of 962,849. The company’s 50-day simple moving average is $36.24 and its 200 day simple moving average is $39.94. The firm has a market cap of $2.15 billion, a P/E ratio of -19.12 and a beta of 0.99. Vera Therapeutics, Inc. has a fifty-two week low of $9.24 and a fifty-two week high of $50.78. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Research analysts anticipate that Vera Therapeutics, Inc. will post -2.59 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Raymond James raised their target price on Vera Therapeutics from $57.00 to $68.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. JPMorgan Chase & Co. cut their target price on Vera Therapeutics from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $42.43.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement Association of Colorado bought a new position in Vera Therapeutics during the second quarter worth about $135,000. Ameritas Investment Partners Inc. lifted its holdings in Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after acquiring an additional 688 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Vera Therapeutics during the second quarter worth about $163,000. Cetera Advisors LLC bought a new position in Vera Therapeutics during the first quarter worth about $235,000. Finally, Capstone Investment Advisors LLC bought a new position in Vera Therapeutics during the first quarter worth about $248,000. 99.21% of the stock is owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.